Search Results for "hansten"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for hansten. Results 11 to 20 of 433 total matches.

Substituting For Troglitazone

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000  (Issue 1076)
ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard, Doris Peter, Ph.D. CONTRIBUTING EDITORS: Philip D. Hansten ...
Full-page advertisements in newspapers are urging patients with type 2 diabetes coming off Rezulin to ask their doctors to switch to Avandia or Actos. Troglitazone was withdrawn from the market on March 21 because of rare but severe hepatic toxicity.
Med Lett Drugs Ther. 2000 Apr 17;42(1076):36 |  Show IntroductionHide Introduction

Cosmetic Phalloplasty

   
The Medical Letter on Drugs and Therapeutics • May 24, 2004  (Issue 1183)
EDITOR: Martin A. Rizack, M.D., Ph.D., Rockefeller University ADVISORY BOARD: Philip D. Hansten, Pharm.D ...
Some patients may be asking healthcare providers about the surgical techniques to enlarge the penis that are widely promoted on the Internet. Phalloplasty was first used to treat traumatic or surgical amputation (for cancer), epispadias and Peyronie's disease (JP Yurkanin et al, J Urol 2001; 166:1769).
Med Lett Drugs Ther. 2004 May 24;46(1183):44 |  Show IntroductionHide Introduction

In Brief: Testing for Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007  (Issue 1264)
EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D., University of Washington ADVISORY BOARD ...
Recent publicity about symptoms of ovarian cancer will prompt many questions from patients about testing for the disease. Early-stage epithelial ovarian cancer is potentially curable, with survival rates of 90-95%, but about 75% of women have advanced or metastatic disease at diagnosis. Between physical examination and exploratory surgery, 2 tests are commonly used.1Transvaginal ultrasound (TVUS) images the ovaries better than transabdominal ultrasound. In a study in which 25,327 asymptomatic women were screened with TVUS annually from 1987 to 2005, 364 patients had exploratory surgery, and 44...
Med Lett Drugs Ther. 2007 Jul 2;49(1264):53 |  Show IntroductionHide Introduction

SSRIs and Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007  (Issue 1274)
EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D., University of Washington ADVISORY BOARD ...
Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is biologically plausible because bone has serotonin receptors, and SSRI-treated mice have reduced bone mass.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):95-6 |  Show IntroductionHide Introduction

In Brief: New Dietary Guidelines

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005  (Issue 1201)
EDITOR: Martin A. Rizack, M.D., Ph.D., Rockefeller University ADVISORY BOARD: Philip D. Hansten, Pharm ...
The US Department of Health and Human Services, in conjunction with the US Department of Agriculture, has released the latest update of its Dietary Guidelines (www.health.gov). The emphasis this time is on weight loss through calorie restriction and exercise. A low-fat intake is recommended; a low-carbohydrate diet is not. Fruits, vegetables and whole grains are encouraged. A review of Diet, Drugs and Surgery for Weight Loss appeared in the December 2003 issue of Treatment Guidelines from The Medical Letter.
Med Lett Drugs Ther. 2005 Jan 31;47(1201):12 |  Show IntroductionHide Introduction

Immunization of College Students Against Meningococcal Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel, M.D., Albert Einstein ...
The US Public Health Service Advisory Committee on Immunization Practices has recently published new recommendations for prevention and control of meningococcal disease in college students.
Med Lett Drugs Ther. 2000 Aug 7;42(1084):69 |  Show IntroductionHide Introduction

In Brief: Natalizumab (Tysabri) Withdrawn

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005  (Issue 1204)
., Rockefeller University ADVISORY BOARD: Philip D. Hansten, Pharm. D., University of Washington Jules Hirsch ...
The February 14th issue of The Medical Letter reviewed natalizumab (Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in patients with multiple sclerosis. On February 28th, the FDA issued a Public Health Advisory announcing that marketing of the drug had been suspended because 2 patients who had been treated with natalizumab for more than 2 years had developed progressive multifocal leukoencephalopathy, a rare, often fatal disease...
Med Lett Drugs Ther. 2005 Mar 14;47(1204):21 |  Show IntroductionHide Introduction

In Brief: Elidel and Protopic

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005  (Issue 1205)
, Pharm.D. ADVISORY BOARD: Philip D. Hansten, Pharm. D., University of Washington Jules Hirsch, M.D ...
The FDA issued a public health advisory on March 10, 2005 warning about a risk of cancer with topical formulations of tacrolimus (Protopic) and pimecrolimus (Elidel) used to treat eczema in adults and children more than 2 years old. Elidel has been heavily promoted to the general public on television. The warning was based on reports of dose-related cancer in animals and 29 reports of cancer (including 8 skin malignancies and 12 lymphomas) in adults and children treated with these immunosuppressive drugs. Cause and effect have not been established. When Protopic was first marketed, The Medical...
Med Lett Drugs Ther. 2005 Mar 28;47(1205):25 |  Show IntroductionHide Introduction

In Brief: Zegerid - Immediate-Release Omeprazole

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2005  (Issue 1206)
OF DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D. ADVISORY BOARD: Philip D. Hansten, Pharm. D ...
The FDA has approved marketing of Zegerid powder for oral suspension (Santarus), an immediate-release formulation of the proton-pump inhibitor (PPI) omeprazole (Prilosec, and others). All other oral PPIs are delayed-release, enteric-coated formulations designed to prevent degradation of the drug by gastric acid. Each 20- or 40-mg packet of Zegerid contains 1680 mg of sodium bicarbonate, which protects the drug from gastric acid degradation. A dose of Zegerid contains 460 mg of sodium, which may be excessive for some patients. Zegerid is the first oral PPI to be approved by the FDA for...
Med Lett Drugs Ther. 2005 Apr 11;47(1206):29 |  Show IntroductionHide Introduction

Azacitidine (Vidaza) for Myelodysplastic Syndrome

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005  (Issue 1201)
: Philip D. Hansten, Pharm. D., University of Washington Jules Hirsch, M.D., Rockefeller University James ...
Azacitidine (Vidaza - Pharmion), a pyrimidine nucleoside analog of cytidine, is the first drug approved by the FDA for treatment of myelodysplastic syndrome (MDS). Azacitidine is incorporated into newly synthesized DNA and inhibits DNA methyltransferase. Hypomethylation of DNA can restore the normal expression of genes critical for cell differentiation.
Med Lett Drugs Ther. 2005 Jan 31;47(1201):11 |  Show IntroductionHide Introduction